Ulf Müller‐Ladner
A5108536388- Rheumatoid Arthritis Research and Therapies
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Dermatologic Treatments and Research
- Mast cells and histamine
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammatory Myopathies and Dermatomyositis
- Osteoarthritis Treatment and Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Cytokine Signaling Pathways and Interactions
- Adipokines, Inflammation, and Metabolic Diseases
- Viral Infections and Immunology Research
- Cell Adhesion Molecules Research
- Connective Tissue Growth Factor Research
- Bone Metabolism and Diseases
- Immunodeficiency and Autoimmune Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Autoimmune Bullous Skin Diseases
- Musculoskeletal synovial abnormalities and treatments
- Bone and Joint Diseases
- Vasculitis and related conditions
- Bone health and treatments
- Biosimilars and Bioanalytical Methods
Kerckhoff Klinik
2016-2025
Justus-Liebig-Universität Gießen
2016-2025
Nuremberg Hospital
2023
University of Zurich
2004-2022
Tameside Hospital
2022
Tameside and Glossop Integrated Care NHS Foundation Trust
2022
University Hospital of Zurich
1998-2021
Center for Rheumatology
2005-2021
Istanbul University
2020
Giessen School of Theology
2005-2019
Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity early SSc and limited cutaneous SSc. present work, by a joint committee the ACR European League Against Rheumatism (EULAR), was undertaken purpose developing new Methods Using consensus methods, 23 candidate items were arranged in multicriteria additive point system with threshold to classify cases as reduced clustering simplifying weights. tested 1) determining...
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
<h3>Objective</h3> The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity early SSc and limited cutaneous SSc. present work, by a joint committee the ACR European League Against Rheumatism (EULAR), was undertaken purpose developing new <h3>Methods</h3> Using consensus methods, 23 candidate items were arranged in multicriteria additive point system with threshold to classify cases as reduced clustering simplifying weights. tested...
<h3>Objectives</h3> To determine the causes and predictors of mortality in systemic sclerosis (SSc). <h3>Methods</h3> Patients with SSc (n=5860) fulfilling American College Rheumatology criteria prospectively followed EULAR Scleroderma Trials Research (EUSTAR) cohort were analysed. EUSTAR centres completed a structured questionnaire on cause death comorbidities. Kaplan–Meier Cox proportional hazards models used to analyse survival subgroups identify mortality. <h3>Results</h3> Questionnaires...
<b>Background:</b> Systemic sclerosis (SSc) is a multisystem autoimmune disease, which classified into diffuse cutaneous (dcSSc) and limited (lcSSc) subset according to the skin involvement. In order better understand vascular, immunological fibrotic processes of SSc guide its treatment, EULAR Scleroderma Trials And Research (EUSTAR) group was formed in June 2004. <b>Aims methods:</b> EUSTAR collects prospectively Minimal Essential Data Set (MEDS) on all sequential patients fulfilling...
<h3>Objective</h3> Earlier detection of pulmonary arterial hypertension (PAH), a leading cause death in systemic sclerosis (SSc), facilitates earlier treatment. The objective this study was to develop the first evidence-based algorithm for PAH SSc. <h3>Methods</h3> In cross-sectional, international conducted 62 experienced centres from North America, Europe and Asia, adults with SSc at increased risk (SSc >3 years predicted diffusing capacity carbon monoxide <60%) underwent broad panel...
To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published 2011. Four systematic literature reviews were performed regarding incidence/prevalence of vaccine-preventable infections among AIIRD; efficacy, immunogenicity and safety vaccines; effect anti-rheumatic drugs on response to household AIIRDs patients. Subsequently, formulated based evidence expert opinion. The updated...
<h3>Objectives</h3> To compare the efficacy and safety of innovator infliximab (INX) CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate (MTX) treatment. <h3>Methods</h3> Phase III randomised, double-blind, multicentre, multinational, parallel-group study. Patients disease despite MTX (12.5–25 mg/week) were randomised receive 3 mg/kg CT-P13 (n=302) or (n=304) folic acid. The primary endpoint was American College Rheumatology 20% (ACR20)...
Purpose: The optimal treatment of systemic sclerosis (SSc) is a challenge because the pathogenesis SSc unclear and it an uncommon clinically heterogeneous disease affecting multiple organ systems. aim European League Against Rheumatism (EULAR) Scleroderma Trials Research group (EUSTAR) was to develop evidence-based, consensus-derived recommendations for SSc. Methods: To obtain maintain high level intrinsic quality comparability this approach, EULAR standard operating procedures were...
Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 2011, we examined certificates all French patients with SSc to death. Then developed a score associated all-cause mortality from international European Scleroderma Trials Research (EUSTAR) database. Candidate prognostic were tested by Cox proportional hazards regression model single variable analysis, followed multiple stratified centres. The bootstrapping technique was used for...
<h3>Objectives:</h3> To develop evidence-based recommendations for the use of methotrexate in daily clinical practice rheumatic disorders. <h3>Methods:</h3> 751 rheumatologists from 17 countries participated 3E (Evidence, Expertise, Exchange) Initiative 2007–8 consisting three separate rounds discussions and Delphi votes. Ten questions concerning disorders were formulated. A systematic literature search Medline, Embase, Cochrane Library 2005–7 American College Rheumatology/European League...
Objective To identify a core set of preliminary items considered as important for the very early diagnosis systemic sclerosis (SSc). Methods A list provided by European League Against Rheumatism (EULAR) Scleroderma Trial and Research(EUSTAR) centres were subjected to Delphi exercise among 110 experts in field SSc. In round 1, asked choose they most 2, reconsider accepted after first stage. 3, clinical relevance selected their importance measures that would lead an referral process rated...
<h3>Objectives</h3> Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. <h3>Methods</h3> The European League Against Rheumatism (EULAR) Scleroderma Trials Research (EUSTAR) group initiated database prospectively gather key data patients with SSc using minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit who were registered between 2004 2011...
Objectives Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) a phase II study. Methods Patients SSc were treated for 48 weeks an open-label extension faSScinate study weekly 162 mg subcutaneous tocilizumab. Exploratory end points included modified Rodnan Skin Score (mRSS) per cent predicted forced vital capacity (%pFVC) through week 96. Results Overall, 24/44 (55%) placebo-tocilizumab 27/43 (63%) continuous-tocilizumab completed Observed mean (SD (95%...
Objective Systemic sclerosis (SSc) is a rare and clinically heterogeneous autoimmune disorder characterised by fibrosis microvascular obliteration of the skin internal organs. Organ involvement mostly manifests after variable period onset Raynaud's phenomenon (RP). We aimed to map incidence predictors pulmonary, cardiac, gastrointestinal (GI) renal in early course SSc. Methods In EUSTAR cohort, patients with SSc were identified as those who had visit within first year RP onset. Incident...
To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).We analysed the Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD for RA at clinical onset (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 (IL-6i) tumour necrosis factor (TNFi, reference group). The ordinal severity...